Systems and methods for destroying or inhibiting cancer cells and other rapidly-dividing cells include coupling an alternating polarity (AP) magnetic field generator to a target body area and applying an AP magnetic field having a frequency of 0.5-500 kHz and a field strength of 0.5-5 mT to the target body area to achieve a desired inhibiting effect on cancer cells or other rapidly-dividing cells. Treatments provided by the system may be co-administered with an anti-cancer drug such as a chemotherapy drug, a hormone therapy drug, targeted therapy drugs, immunotherapy drugs, or an angiogenesis inhibitor drug.

A system for injecting includes a syringe body defining a proximal opening and a distal needle interface. The system also includes a plunger member defining a plunger interior and configured to be manually manipulated to insert a stopper member relative to the syringe body. The plunger member includes a needle retention feature disposed in the plunger interior, an energy-storage member disposed in the plunger interior, and an energy-storage member latching member disposed in the plunger interior. The system further includes a needle hub assembly coupled to the distal needle interface of the syringe body. The needle assembly includes a needle having a needle proximal end feature, a hub, and a needle latching member configured to couple the needle to the hub. The needle is retractable into plunger interior upon manipulation of the plunger member to actuate the energy-storage member latching member.

A top for a plasma storage container includes a top body that defines the structure of the top and seals an opening of the plasma storage container. The top also includes a first opening and a vent opening extending through the top body. A septum is located at least partially within the first opening and includes an aperture therethrough. The septum allows a blunt cannula to pass through the aperture to access the interior of the plasma storage container. The top also includes a hydrophobic membrane located on underside of the top body. The membrane covers the vent opening and allows air to vent through the vent opening during plasma collection.

The embodiments of the present disclosure provide a pierceable stopper, comprising a plug portion, and a disk portion disposed on top of the plug portion and comprising a flange extending radially beyond an outer diameter of the plug portion. The embodiments also provide a lyophilization stopper, comprising a body comprising an integral hinge means, and a flange extending radially beyond an outer diameter of the body. Additionally, the embodiments provide a probe assembly, comprising a first needle comprising a hollow cavity and a pointed tip, and a second needle disposed inside the hollow cavity and comprising a rounded tip. The embodiments further provide a cartridge assembly, comprising a first housing comprising a first set of cavities configured to accommodate one or more containers, and a second housing comprising a second set of cavities corresponding to the first set of cavities when the second housing is coupled to the first housing.

A medical system is disclosed. The medical system has a housing and a module received in the housing. The module includes an analyte sensor configured for detecting an analyte in a body fluid of a user, an electronics unit electrically connected to the analyte sensor, an insertion component configured for inserting the analyte sensor into body tissue of the user, and a sterility cap at least partially surrounding the insertion component. A removable protective cap is connected to the housing and covers the module. The protective cap at least partially surrounds the sterility cap. The sterility cap has a sterility testing access that has at least one of a septum and a multiple-step sealing. A method of sterility testing the medical system is also disclosed in which a rinsing liquid is inserted into an interior space of the sterility cap and microbial testing of the rinsing liquid is then completed.

A device for connecting tubes for a drug delivery system includes a connecting portion having a first tube channel, a second tube channel, a connecting heating element, and a carriage assembly. The first tube channel is adapted to receive a first tube, and the second tube channel is adapted to receive a second tube. The connecting heating element is positioned adjacent to and/or intersecting the first and second tube channels and is adapted to selectively heat at least a portion of the first and second tube. The carriage assembly moves the heated first and second tubes into end-to-end contact with each other to couple the first and second tubes together.

Various embodiments are disclosed herein related to fluidic connections for modules useable in combinatorial drug delivery devices. The fluidic connections allow for variable flow paths to be defined for serially-connected, and base-tray mounted, modules.

A drug delivery device comprising a delivery unit (2) including an internal reservoir (8), a subcutaneous delivery mechanism (6), a pump for pumping liquid from the internal reservoir to the subcutaneous delivery system, and a liquid filling mechanism (12) configured for injecting liquid from an external vial (16) or reservoir into the internal reservoir. The liquid filling mechanism comprises a filling port (14) and a valve mechanism (18) selectively operable to: open a first fluid path (54) extending from the filling port to the internal fluid reservoir and close a second fluid path (56) extending from the internal reservoir to the subcutaneous delivery member, or close the first fluid path and open the second fluid path. The valve mechanism comprises a valve housing (48) fixedly mounted in relation to a housing of the drug delivery device and a valve stem (50) rotatably received within the valve housing, whereby the first fluid path and the second fluid path are selectively operated by the rotational position of the valve stem in relation to the valve housing, such that when the valve stem is in a first position, the first fluid path is open while the second fluid path is closed, and when the valve stem is in a second position, the second fluid path is open while the first fluid path is closed.

A system is disclosed for producing a mixture to deliver to a treatment site. The system can include a connector with a connector vent so that air in the connector is expellable therethrough. A multi-lumen chamber can be connected to a proximal end of the connector and include a first lumen aligned and adjacent a second lumen. The first lumen can be configured to include a first constituent in a proximal portion of the first lumen, a second constituent in a distal portion of the first lumen, and a first plunger internally positioned within the first lumen to distally move the first constituent into the distal portion to mix with the second constituent in a first state to form a first mixture. The second lumen is configured to include a third constituent and a second plunger rod internally positioned within the second to distally move the third constituent.

An injection port assembly may comprise a support body having a receptacle associated with a passage through the support body. The receptacle may have at least one recess in an end surface of the receptacle. The receptacle may have a plurality of retainer members. The assembly may further comprise a peripheral rim rib about a periphery of the support body and a number of additional ribs extending from the receptacle to the peripheral rim rib. The assembly may further comprise a delivery assembly coupled within the receptacle via the retainer members. The delivery assembly may have a cannula extending through the passage. The delivery assembly may have an injection receiving volume within the delivery assembly in fluid communication with a lumen of the cannula but otherwise fluidically sealed by a self-sealing barrier. There may be a sole externally accessible portion of the barrier aligned with an axis of the lumen.